Interestingly, whilst there was no influence of hypertension and smoking status, patients with clinically defined dyslipidaemia had significantly increased GlycA, but no difference in ApoA1, supporting the use of these biomarkers for CVD risk assessment (Supplementary Fig. S4B–D, available at Rheumatology online). The gene discussed is APOA1; the disease is Hypertension.